throbber
test@unify.com
`To: kamila.alberti-correa@meltmedia.com
`Proven survival benefit for your HER2+ MBC patients
`
`
`
`Dear [Healthcare Provider Name]:
`
`November 11, 2013 11:14 AM
`
`[Customize the text in this paragraph with your own message to the Healthcare Provider. Based on
`Regulatory requirements, you may only include a 500-character message with the preformatted HTML e-
`mail. This includes the signature.]
`
`[Signature]
`KADCYLA demonstrated clinical benefits in patients
`with HER2+ MBC
`
`Proven survival
`benefit1
`
`Indication
`KADCYLA® (ado-trastuzumab emtansine), as a
`single agent, is indicated for the treatment of patients
`with HER2-positive (HER2+), metastatic breast
`cancer (MBC) who previously received trastuzumab
`and a taxane, separately or in combination. Patients
`should have either:
`• Received prior therapy for metastatic disease, or
`• Developed disease recurrence during or within six
`months of completing adjuvant therapy
`
`KADCYLA is the first HER2-targeted antibody-drug conjugate for
`HER2+ metastatic breast cancer.
`In the Phase III EMILIA trial of KADCYLA vs the combination of
`lapatinib + capecitabine, KADCYLA extended median overall survival
`(OS) and significantly improved median progression-free survival (PFS).
`KADCYLA extended median OS by nearly 6 months1
`PRIMARY ENDPOINT: OVERALL SURVIVAL (OS)
`
`IMMUNOGEN 2235, pg. 1
`Phigenic v. Immunogen
`IPR2014-00676
`
`

`
`Results of the randomized, open-label, Phase III EMILIA trial of KADCYLA (3.6 mg/kg IV, Day 1) vs the
`combination of lapatinib (1250 mg/day oral, once daily) and capecitabine (1000 mg/m2, oral, twice daily, Days 1-
`14) in 21-day cycles until disease progression in HER2+ MBC patients previously treated with trastuzumab and a
`taxane. Primary endpoints were OS, progression-free survival (PFS), and safety.1,2
`50% improvement in median PFS by independent review1
`• 9.6 months median PFS with KADCYLA vs 6.4 months with lapatinib + capecitabine;
`P<0.0001
`
`Boxed WARNINGS: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-​FETAL TOXICITY
`• Do Not Substitute KADCYLA for or with Trastuzumab
`• Hepatotoxicity: Serious hepatotoxicity has been reported, including liver failure and
`death in patients treated with KADCYLA. Monitor serum transaminases and bilirubin
`prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Reduce
`dose or discontinue KADCYLA as appropriate in cases of increased serum
`transaminases or total bilirubin
`• Cardiac Toxicity: KADCYLA administration may lead to reductions in left ventricular
`ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and
`during treatment with KADCYLA. Withhold treatment for clinically significant decrease
`in left ventricular function
`• Embryo-​Fetal Toxicity: Exposure to KADCYLA can result in embryo-fetal death or birth
`defects. Advise patients of these risks and the need for effective contraception
`
`For more information about these and other
`EMILIA trial endpoints, visit KADCYLA.com.
`
`Important Safety Information
`Additional Important Safety Information
`Left Ventricular Dysfunction (LVD)
`• Patients treated with KADCYLA are at increased risk of developing LVD. In EMILIA, LVD
`occurred in 1.8% of patients in the KADCYLA-treated group and in 3.3% in the comparator
`group. Permanently discontinue KADCYLA if LVEF has not improved or has declined further
`Pregnancy Registry
`• Advise patients to contact their healthcare provider immediately if they suspect they may be
`pregnant. Encourage women who may be exposed to KADCYLA during pregnancy to enroll in
`the MotHER Pregnancy Registry by contacting 1-800-690-6720
`Pulmonary Toxicity
`• Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute
`respiratory distress syndrome or fatal outcome have been reported in clinical trials with
`KADCYLA. In EMILIA, the overall frequency of pneumonitis was 1.2%
`• Treatment with KADCYLA should be permanently discontinued in patients diagnosed with ILD
`or pneumonitis
`Infusion-Related Reactions, Hypersensitivity Reactions
`• Treatment with KADCYLA has not been studied in patients who had trastuzumab permanently
`discontinued due to infusion-related reactions (IRR) and/or hypersensitivity reactions;
`treatment with KADCYLA is not recommended for these patients. In EMILIA, the overall
`frequency of IRRs in patients treated with KADCYLA was 1.4%
`• KADCYLA treatment should be interrupted in patients with severe IRR and permanently
`discontinued in the event of a life-threatening IRR. Patients should be closely monitored for
`IRR reactions, especially during the first infusion
`
`IMMUNOGEN 2235, pg. 2
`Phigenic v. Immunogen
`IPR2014-00676
`
`

`
`Thrombocytopenia
`• In EMILIA, the incidence of ≥ Grade 3 thrombocytopenia was 14.5% in the KADCYLA-treated
`group and 0.4% in the comparator group (overall incidence 31.2% and 3.3%, respectively)
`• Monitor platelet counts prior to initiation of KADCYLA and prior to each KADCYLA dose.
`Institute dose modifications as appropriate
`Neurotoxicity
`• In EMILIA, the incidence of ≥ Grade 3 peripheral neuropathy was 2.2% in the KADCYLA-
`treated group and 0.2% in the comparator group (overall incidence 21.2% and 13.5%,
`respectively)
`• Monitor for signs or symptoms of neurotoxicity. KADCYLA should be temporarily discontinued
`in patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to
`≤ Grade 2
`HER2 Testing
`• Detection of HER2 protein overexpression or gene amplification is necessary for selection of
`patients appropriate for KADCYLA. Perform using FDA approved tests by laboratories with
`demonstrated proficiency
`Extravasation
`• In KADCYLA clinical studies, reactions secondary to extravasation have been observed and
`were generally mild. The infusion site should be closely monitored for possible subcutaneous
`infiltration during drug administration. Specific treatment for KADCYLA extravasation is
`unknown
`Nursing Mothers
`• Discontinue nursing or discontinue KADCYLA taking into consideration the importance of the
`drug to the mother
`Adverse Reactions
`• The most common ADRs seen with KADCYLA in EMILIA (frequency > 25%) were nausea,
`fatigue, musculoskeletal pain, thrombocytopenia, increased transaminases, headache, and
`constipation. The most common NCI-CTCAE (version 3) ≥ Grade 3 ADRs (frequency >2%)
`were thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral
`neuropathy and fatigue
`You are encouraged to report side effects to Genentech and the FDA. You may contact
`Genentech by calling 1-888-835-2555. You may contact the FDA by visiting
`www.fda.gov/medwatch or calling 1-800-FDA-1088.
`Please download the full Prescribing Information for additional important safety
`information, including Boxed WARNINGS.
`For more information on KADCYLA, visit KADCYLA.com.
`
`References: 1. KADCYLA Prescribing Information. Genentech, Inc. May 2013. 2. Verma S,
`Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive
`advanced breast cancer [published correction appears in N Engl J Med. 2013;368:2442]. N Engl
`J Med. 2012;367:1783-1791 and Supplementary Appendix.
`
`TDM0002192700 (11/13)
`
`Privacy Policy | Terms and Conditions | Contact Genentech®
`
`This e-mail is intended for U.S. healthcare professionals only.
`
`To unsubscribe from this type of informational e-mail as delivered by your Genentech
`representative, please click here. Regular communications between you and your Genentech
`representative regarding standard business and meeting coordination activities may continue.
`
`© 2013 Genentech USA, Inc. All rights reserved.
`
`Genentech, Inc.
`1 DNA Way
`South San Francisco, CA
`94080-4990
`
`IMMUNOGEN 2235, pg. 3
`Phigenic v. Immunogen
`IPR2014-00676
`
`

`
`IMMUNOGEN 2235, pg. 4
`Phigenic v. Immunogen
`|PR2014-00676
`
`IMMUNOGEN 2235, pg. 4
`Phigenic v. Immunogen
`IPR2014-00676

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket